RecruitingPhase 2NCT06016634

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease

Sponsor

University of California, Davis

Enrollment

30 participants

Start Date

Mar 9, 2026

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease Osteonecrosis Avascular Necrosis Sickle Cell Anemia Ischemic Necrosis

Summary

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Alendronate Sodium for people with avascular necrosis, ischemic necrosis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAlendronate Sodium

Administer oral alendronate 70 mg once a week x 24 weeks to all study participants

Locations(1)

UC Davis Comprehensive Cancer Center

Sacramento, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06016634

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT065466709 locations